Ovid currently has several ongoing corporate partnerships:
Angelini Pharma
In July 2020, Ovid and Angelini Pharma, an Italian family-owned pharmaceutical company committed to helping patients with a constant and prevalent focus on mental health, rare diseases, and consumer health, entered into an exclusive license agreement to develop, manufacture, and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome. OV101 is a delta (δ)-selective GABAA receptor agonist. Under the terms of the agreement, Angelini Pharma obtained exclusive development, manufacturing, and commercialization rights to OV101 in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdom, and Russia.
Read Ovid press release »
Read Angelini press release »
Takeda
In January 2017, Takeda and Ovid began an innovative clinical development and commercialization collaboration partnership to develop OV935/TAK-935 (soticlestat), a highly selective first-in-class CH24H inhibitor with the potential to reduce seizure susceptibility and improve seizure control in rare developmental and epileptic encephalopathies (DEE). As part of this agreement, Ovid leads clinical development activities and commercialization in the United States, Europe, Canada and Israel. Takeda will lead commercialization in Japan, and has the option to lead in Asia and other selected geographies.
Read Ovid press release »
Read Takeda press release »
Lundbeck
In March 2015, Ovid entered into an exclusive worldwide license agreement for OV101 (gaboxadol) with Lundbeck, a global pharmaceutical company specialized in brain diseases. OV101, a highly selective GABAA receptor (GABAAR) agonist, has been tested in clinical trials and holds the potential to be the first oral medication to treat patients with Angelman syndrome and Fragile X syndrome. Under the terms of the agreement, Ovid obtained exclusive worldwide development and commercialization rights for OV101 and is responsible for all future development and commercialization for OV101.
Read Ovid press release »